Flot.bio x Philip Hemme

Flot.bio
  • ٠٫٠ (٠)
  • علوم حياة
  • يتم التحديث شهريًا
Flot.bio x Philip Hemme

Watch the best Europeans in biotech to grow. Hosted by Philip Hemme. 10k monthly views. Free. Guests include Antoine Papiernik @Sofinnova, Werner Lanthaler @Evotec, Ingmar Hoerr @CureVac, Bernat Olle @Vedanta, Johannes Fruehauf @BioLabs, Rodger Novak @CRISPR Tx, Agnete Fredriksen @Nykode, Mike Ward, Thomas Clozel @Owkin, Marc de Garidel @Abivax, and Sander van Deventer @VectorY & Forbion. Your host Philip animates the conversation to dig out exciting, and sometimes contrarian ideas.

  1. Gunilla Osswald, BioArctic 🇸🇪 | Leqembi, Alzheimer’s disease | E26

    ٠٨‏/٠٦‏/١٤٤٦ هـ

    Gunilla Osswald, BioArctic 🇸🇪 | Leqembi, Alzheimer’s disease | E26

    We’re at BIO-Europe in Stockholm 🇸🇪 with Gunilla Osswalld, the CEO of BioArctic, the inventor of one of the only drugs that have worked for Alzheimer's. We talked about the science and business behind Leqembi. We also talked about the Alzheimer’s field at large and transitioning from big pharma to biotech. — — — Thank you to today’s sponsor, Turbine, who is organizing a free Techbio event at JPM25 and is inviting you to join. Click the link to RSVP and secure one of the limited spots: https://www.turbine.ai/jpm25-event-registration — — — ⭐️ ABOUT THE SPEAKER Gunilla joined BioArctic in 2013 after many successful years in executive positions at Astra/AstraZeneca, including Vice President for the product portfolio of neurodegenerative diseases. Since joining BioArctic, the largest Swedish biotech, Leqembi, one of the only successful drugs for Alzheimer’s was approved. This was an invention of BioArctic that Eisai and Biogen have commercialized. This is a particularly impressive feat considering 98% of Alzheimer’s drugs fail. 🔗 LINKS MENTIONED- The CEO of BioArctic talks Leqembi and what's next in Alzheimer's, Parkinson's, ALS, and more: https://www.biotechtv.com/post/bioarctic-gunilla-osswald-september-21-2024 - Roche sees rapid amyloid clearing in Alzheimer's study, adjusts protocol after patient death: https://www.fiercebiotech.com/biotech/roche-sees-rapid-amyloid-clearing-early-alzheimers-study - Edwin Moses | How to build large biotech platforms | E13: https://flot.bio/episode/edwin-moses-biotech-platforms/ 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/gunilla-osswald-bioarctic-alzheimers/ 💸 DONATE We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free. ⏰ TIMESTAMPS [00:00:00] Intro [00:02:24] Leqembi and BioArctic [00:10:40] Side effects of Leqembi for Alzheimer's treatment [00:17:03] Passing the blood-brain barrier for better Alzheimer's treatments [00:21:00] Market access for Leqembi in Europe [00:27:03] Gunilla Osswald's commitment to patients [00:31:55] Leaving AstraZeneca, transitioning to biotech [00:38:42] Unique culture at BioArctic [00:42:26] Alzheimer's field in Europe and at large [00:48:20] Quickfire [00:53:42] Thanks for listening

    ٥٤ من الدقائق
  2. Sean Marett 🇩🇪 | BioNTech, Art of Dealmaking | E25

    ٠١‏/٠٦‏/١٤٤٦ هـ

    Sean Marett 🇩🇪 | BioNTech, Art of Dealmaking | E25

    We’re in Hamburg with Sean Marett, who has been instrumental to the success of BioNTech for 12 years. We talked about the secrets behind BioNTech’s success. We also talked about the art of dealmaking and working with China. ⭐️ ABOUT THE SPEAKER Sean joined BioNTech in 2012 as part of the Management Board. He was instrumental in the growth of the company and global expansion through business development and product commercialization. Prior to BioNTech Sean worked in top companies such as GlaxoSmithKline, Pfizer, Evotec, and Lorantis. I first met Sean in 2015 in Berlin, when BioNTech had no website, but was already the largest private biotech in Europe. Now Sean has retired from BioNTech after 12 years but still aids the company as a specialist consultant. 🔗 LINKS MENTIONED - BioNTech Announces Planned Retirement of Sean Marett: https://investors.biontech.de/news-releases/news-release-details/biontech-announces-planned-retirement-sean-marett - BioNTech pays $800M to take control of potential Keytruda killer: https://www.fiercebiotech.com/biotech/biontech-pays-800m-take-control-potential-keytruda-killer - Sean Marett, COO at BioNTech, on the Future of mRNA Therapies - 2015: https://www.youtube.com/watch?v=6zrDKRvsAEU 📜 TRANSCRIPT Read the full transcript here: 💸 DONATE We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free. ⏰ TIMESTAMPS - [00:00:00] Intro - [00:01:45] Sean Marett stepping down as CBO of BioNTech - [00:05:10] From Pfizer to BioNTech - [00:15:28] Building a biotech in Mainz - [00:29:02] The art of biotech dealmaking - [00:45:29] Mistakes in dealmaking - [00:57:45] Biotech dealmaking in China - [01:04:25] Managing energy - [01:08:17] Quickfire - [01:13:57] Thanks for listening

    ١ س ١٥ د
  3. Lovisa Afzelius, Flagship Pioneering 🇸🇪 | Company building, AI | E24

    ١٦‏/٠٥‏/١٤٤٦ هـ

    Lovisa Afzelius, Flagship Pioneering 🇸🇪 | Company building, AI | E24

    In our first episode recorded live in front of an audience, we’re with Lovisa Afzelius, the General Partner of the European branch of Flagship Pioneering 🇸🇪 We talk about Flagship, including its EU activities. We also talk about company-building and Lovisa’s personal journey to be one of the leading Swedish leaders in biotech. ⭐️ ABOUT THE SPEAKER Lovisa is an icon in the EU biotech and pharma world, having been a CEO, co-founder, president, board chairman, and executive director in many emerging companies. Joining Flagship in 2020, she became the founding CEO of Alltrna, and co-founded/CEO of Apriori Bio, Metaphore Biotechnologies, and Prologue Medicines. Lovisa has received many accolades. A few include being listed on Inc. Magazine’s Female Founders 250 List in 2024, 2023 she featured in the PharmaVoice 100 list of life science industry leaders. 🔗 LINKS MENTIONED - tRNA therapies, Lovisa Afzelius, Founding CEO, Theonie Anastassiadis, Co-founder & CIO, Alltrna: https://open.spotify.com/episode/3JaGad1YednEhExnK4Xl2L?si=7G65_6u_TyeB3Rmn5hzZYw&nd=1&dlsi=4f17dae5cf3f4306 - Agnete Fredriksen, Nykode | Being one of the top 50 women in 🇪🇺 Bio | E07: https://flot.bio/episode/agnete-fredriksen-top-women-bio/ - Flagship Pioneering website: https://www.flagshippioneering.com/ - Otello Stampacchia, Omega Funds 🇮🇹 | Competition, Boston & Pasta | E18: https://flot.bio/episode/otello-stampacchia-omega-funds/ 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/lovisa-afzelius-flagship-pioneering/ 💸 DONATE We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 20k monthly views. Free. ⏰ TIMESTAMPS [00:00:00] Intro [00:02:08] Flagship Pioneering and their EU biotech initiatives [00:06:18] Being creative in many biotech spheres [00:08:37] Why invest 50m in first seed Series A every time? [00:11:42] The Flagship Pioneering business model: invest early [00:15:57] VC-created vs founder-led biotechs [00:17:46] Raising one of the largest biotech funds [00:19:19] Flagship Pioneering’s biggest returns [00:22:36] AI & biotech [00:26:31] What does success mean to Flagship Pioneering [00:29:20] How to help biotech spinoffs grow and advice for women to be biotech leaders [00:34:03] How to move from computational to translation sciences & bring drugs to market faster [00:37:14] What can the EU learn from the US to create biotechs [00:40:36] How do you bridge the gap between biotech company creation in the US vs EU [00:43:07] Lessons for an early-stage biotech career [00:47:18] How to attract the best biotech talent [00:48:38] Moving to Boston [00:52:13] Quickfire [00:55:41] Thanks for listening

    ٥٩ من الدقائق
  4. Szabolcs Nagy, Turbine 🇭🇺 | AI in Biotech, Simulation | E23 [Sponsored]

    ٠٩‏/٠٥‏/١٤٤٦ هـ

    Szabolcs Nagy, Turbine 🇭🇺 | AI in Biotech, Simulation | E23 [Sponsored]

    We’re in Budapest with Szabolcs Nagy, the founder of Turbine, one of the leading companies for AI in biotech in the world. We talked about AI in biotech at large. We also cover the differences between opening a platform versus doing proprietary drug development and building the company from central Europe. __ This episode is sponsored by Turbine, which can improve your drug development. Learn more at https://shorturl.at/w3Im6 __ ⭐️ ABOUT THE SPEAKER I’ve known Szabolcs since 2017 when he joined Bayer’s accelerator in Berlin. I found him incredibly inspiring back then and still to this day. Szabi began his serial entrepreneurship with the creation of a cybersecurity startup. Once that was acquired, he launched himself into the biotech scene with the founding of Turbine in 2015. 🔗 LINKS MENTIONED - Accenture's Investment in Turbine Enhances AI-Powered Cell Simulations for Biopharma R&D: https://www.biopharmatrend.com/post/806-accentures-investment-in-turbine-enhances-ai-powered-cell-simulations-for-biopharma-rd/ - After a tough year, Exscientia folds into Recursion to create an AI superpower: https://www.fiercebiotech.com/biotech/after-tough-year-exscientia-folds-recursion-create-ai-super-power 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/szabolcs-nagy-ai/ 💸 DONATE We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. [🎙️](https://x.com/FlotBio) ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 20k monthly views. Free. ⏰ TIMESTAMPS [00:00:00] Intro [00:01:47] AI in Biotech [00:09:03] Open platform vs proprietary drug development [00:29:09] Pricing and value of AI technology in biotech [00:38:19] Working with the average biotech [00:42:42] History of Turbine and Szabolcs Nagy [00:53:36] Data-driven drug development [00:58:04] Quickfire

    ١ س ٥ د
  5. Adrian Rawcliffe, Adaptimmune 🇬🇧 | Tecelra, TCR Cell Therapy, Solid Tumors | E22

    ٢٥‏/٠٤‏/١٤٤٦ هـ

    Adrian Rawcliffe, Adaptimmune 🇬🇧 | Tecelra, TCR Cell Therapy, Solid Tumors | E22

    We’re online with Adrian Rawcliffe, the CEO of Adaptimmune, the TCR cell therapy company behind the first engineered cell therapy for solid tumors that was approved for a rare form of sarcoma. We talked about Tecelra's commercial rollout. We also talked about what's next in cell therapy, and Philly Cheesesteak vs Fish and Chips. — — — Thank you to today’s sponsor, Merck, who can support your antibody drug discovery. Learn more and claim a cool antibody pin here: https://bit.ly/3AhZFUA — — — ⭐️ ABOUT THE SPEAKER Adrian Rawcliffe has been in the biopharma industry for over 20 years and has worked in high positions for companies such as GSK. Adrian has been with Adaptimmune for almost 10 years, serving as CFO before becoming the CEO in 2019. I didn’t know him personally but have heard and seen great things about him. 🔗 LINKS MENTIONED - US FDA approves Adaptimmune's therapy for rare type of cancer: https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-adaptimmunes-gene-therapy-rare-cancer-2024-08-02/ - Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor: https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/271/adaptimmune-receives-u-s-fda-accelerated-approval-of - Galapagos selects Adaptimmune T-cell therapy for $665M biobucks collab: https://www.fiercebiotech.com/biotech/galapagos-selects-adaptimmune-t-cell-therapy-665m-biobucks-collab - FDA approves Iovance's Amtagvi as first T-cell therapy for a solid tumor: https://www.fiercepharma.com/pharma/fda-approves-iovances-amtagvi-first-cell-therapy-solid-tumor - Fireside Chat with Adrian Rawcliffe, Chief Executive Officer of Adaptimmune: https://www.youtube.com/watch?app=desktop&v=AWIbHOJ1nUI&t=1121s - Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)00319-2/abstract - Adaptimmune's CEO discusses last night's FDA accelerated approval of TECELRA, a TCR-based engineered cell therapy for synovial sarcoma: https://www.biotechtv.com/post/adaptimmune-august-2-2024 - Adrian’s LinkedIn profile: https://www.linkedin.com/in/adrawcliffe/ 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/adrian-rawcliffe-adaptimmune/ 💸 DONATE We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free. ⏰ TIMESTAMPS [00:00:00] Introducing Adrian Rawcliffe [00:02:35] Commercial rollout of Tecelra, the first engineered cell therapy for solid tumors [00:07:35] The limits of TCR Cell Therapy [00:13:54] Market access in Europe [00:15:36] Peak sales projections [00:21:34] Next steps into 2025 [00:22:23] Rich History of Adaptimmune [00:28:47] GSK and transitioning to Biotech [00:35:54] BD & Partnering (or why not partner)[00:44:47] The Future of Cell Therapy: When will Allogeneic and In Vivo Therapies be on the Market? [00:48:43] Quick fire with Adrian Rawcliffe[00:50:20] Thanks for listening

    ٥٤ من الدقائق
  6. Marina Udier, Nouscom 🇨🇭 | Cancer Vaccines, Neoantigens | E21

    ٢٨‏/٠٣‏/١٤٤٦ هـ

    Marina Udier, Nouscom 🇨🇭 | Cancer Vaccines, Neoantigens | E21

    We’re in Basel 🇨🇭 with the CEO of Nouscom, one of the top EU immuno-oncology biotechs in the cancer vaccine space, Marina Udier. We talked about cancer vaccines and Nouscom’s platform. We also discussed the importance of focus for success and her career. ⭐️ ABOUT THE SPEAKER Marina was recommended to me by one of her investors. She has an inspiring story, growing up in Croatia, going to the US, and making it all the way to be one of the 11% of female CEOs of biotechs in Europe in 2024. Now she is the CEO of Nouscom, but prior she was the Operating Principal at Versant Ventures, as well as holding top-level positions at Novartis Pharma, and McKinsey & Company. 🔗 LINKS MENTIONED - Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial - ****https://investors.modernatx.com/news/news-details/2022/Moderna-and-Merck-Announce-mRNA-4157V940-an-Investigational-Personalized-mRNA-Cancer-Vaccine-in-Combination-with-KEYTRUDAR-pembrolizumab-Met-Primary-Efficacy-Endpoint-in-Phase-2b-KEYNOTE-942-Trial/default.aspx?os=vb&ref=app - Agnete Fredriksen, Nykode | Being one of the top 50 women in 🇪🇺 bio | E07 - https://flot.bio/episode/agnete-fredriksen-top-women-bio/ - BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024 - https://investors.biontech.de/news-releases/news-release-details/biontech-present-clinical-data-updates-across-mrna-and - Nouscom Raises €67.5 Million ($72 Million) In Oversubscribed Series C Financing Round - https://nouscom.com/2023/11/14/nouscom-raises-e67-5-million-72-million-in-oversubscribed-series-c-financing-round-2-2/ 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/marina-udier-nouscom-cancer-vaccines/ 💸 DONATE We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. [🎙️](https://x.com/FlotBio) ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free. ⏰ TIMESTAMPS - [00:00:00] Intro - [00:02:18] Cancer vaccines & Nouscom - [00:10:39] Bioinformatics algorithm - [00:15:16] Hype cycle in cancer vaccines - [00:26:04] $72M series C - [00:33:35] Managing a biotech board - [00:42:22] Personal story of Marina Udier - [00:48:17] Transition from Novartis - [00:54:00] Luck and timing in biotech - [00:56:10] Headwinds, Tailwinds - [00:58:13] Finding focus with a small team - [01:06:33] Gender diversity in biotech - [01:16:01] Quick fire - [01:18:37] Thanks for listening

    ١ س ٢٠ د
  7. Harpreet Singh, Immatics 🇩🇪 | PRAME, TCR Based Therapeutics | E20

    ٢٩‏/٠٢‏/١٤٤٦ هـ

    Harpreet Singh, Immatics 🇩🇪 | PRAME, TCR Based Therapeutics | E20

    We’re in Munich 🇩🇪 with the founder of one of the 15 most valuable European biotechs, Harpreet Singh. We talked about the field of PRAME receptors, TCR therapeutics and cell therapy at large. We also talked about the combination with mRNA therapeutics and his upbringing in a Sikh family in Germany. 🔗 LINKS MENTIONED Labiotech.eu | “Interview Harpreet Singh - Why Being in a New Field From the Start Can Pay Off in the Long Run”, Sep 2019: https://www.labiotech.eu/expert-advice/interview-singh-immatics/ Flot.bio | “Bahija Jallal, Immunocore 🇬🇧 | Commercial, Diversity, and AI | E14”, Mar 2024: https://www.youtube.com/watch?v=8bmGke4sRvE Edwin Moses | How to Build Large Biotech Platforms (like Ablynx) | E13: https://youtu.be/oMBcFC3PqyM?si=xTcZF27F0UFjyQhb ApexOnco | Immatics’ PRAME gift keeps on giving: https://www.oncologypipeline.com/apexonco/immatics-prame-gift-keeps-giving 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/harpreet-singh-immatics/ 💸 DONATE We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free. ⏰ TIMESTAMPS [00:00:00] Intro [00:02:00] PRAME & TCR space [00:12:43] Types of Cell Therapy [00:25:44] Commercialization [00:29:11] Valuations in Gene Therapy [00:33:17] Fundraising with Dievini and Struengmann [00:43:46] Sikh origin [00:48:31] Expanding to the US [00:53:59] PhD to CEO [00:59:21] Quickfire [01:03:01] Thanks for listening

    ١ س ٤ د
  8. Dominik Schumacher, Tubulis 🇩🇪 | Founder-led ADC Biotech ⭐️ | E19

    ٠٩‏/٠١‏/١٤٤٦ هـ

    Dominik Schumacher, Tubulis 🇩🇪 | Founder-led ADC Biotech ⭐️ | E19

    We’re in Munich 🇩🇪 with a “true” biotech founder, Dominik Schumacher of Tubulis. Not many biotechs in Europe are led by a founder PhD under 40 and have scaled to raising over 100M. I know only two, one is Thomas at Owkin and the other one is Dominik at Tubulis. We talked about building a champion ADC biotech, the super hot ADC sphere, and the difference between luck and success. 💎 ABOUT THE SPEAKER Dominik has had an incredible career, which he started from a young age. With the founding of Tubulis, he has won many start-up awards and in 2019 he was awarded MIT’s Innovators Under 35. As a life science investor, he has invested early in many European biotech companies. 🔗 LINKS MENTIONED - https://curie.bio/ - https://curie.bio - Tubulis Closes Upsized €128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline - https://tubulis.com/news/tubulis-closes-upsized-e128-million-series-b2-to-accelerate-clinical-development-of-solid-tumor-focused-adc-pipeline/ - BioSpace - Next wave of ADCs - https://www.biospace.com/article/the-next-wave-of-adcs-could-treat-evasive-solid-tumors-/ - BMS axes Eisai ADC pact 3 years after paying $650M for would-be Elahere rival - https://www.fiercebiotech.com/biotech/bms-axes-eisai-adc-pact-3-years-after-paying-650m-would-be-elahere-rival - Merck’s ADC Pact With Daiichi Hits Regulatory Setback in FDA Rejection - https://www.biospace.com/article/merck-s-adc-pact-with-daiichi-hits-regulatory-setback-with-fda-rejection/ - ADC Space is too crowded? - https://drive.google.com/file/d/1oA23bidvd2G-z2lnAkPLAMZgl1RXLtr9/view?usp=sharing - Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio ($1.8B cash) - https://ir.genmab.com/news-releases/news-release-details/genmab-broaden-and-strengthen-oncology-portfolio-acquisition - BIO-Europe Spring 2019: Newcomer Tubulis tackles ADC technology shortcomings - https://www.youtube.com/watch?v=wwr5KMypBHs - Top 20 Healthcare Specialist Investors - https://drive.google.com/file/d/1r4IwIKvuVUYQaqCZnpm4DtEYyy3LIT7h/view?usp=sharing 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/dominik-schumacher-tubulis/ 💸 DONATE We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free. ⏰ TIMESTAMPS [00:00:00] Intro [00:01:44] Entrepreneurial biotech family [00:08:46] Market validation [00:14:32] Why Munich [00:17:33] Founder-led biotechs [00:25:20] Balancing 3 kids [00:29:31] Tubulis & ADCs [00:38:25] ADC space is crowded [00:46:12] Deep Track Capital [00:48:17] Vision for Tubulis [00:52:59] ADC space is hot [00:58:03] Chinese biotech [01:02:53] Luck vs success

    ١ س ٩ د
مشاهدة الكل (٢٦)

حول

Watch the best Europeans in biotech to grow. Hosted by Philip Hemme. 10k monthly views. Free. Guests include Antoine Papiernik @Sofinnova, Werner Lanthaler @Evotec, Ingmar Hoerr @CureVac, Bernat Olle @Vedanta, Johannes Fruehauf @BioLabs, Rodger Novak @CRISPR Tx, Agnete Fredriksen @Nykode, Mike Ward, Thomas Clozel @Owkin, Marc de Garidel @Abivax, and Sander van Deventer @VectorY & Forbion. Your host Philip animates the conversation to dig out exciting, and sometimes contrarian ideas.

المعلومات

  • صناع العمل
    Flot.bio
  • سنوات النشاط
    ١٤٤٤ هـ - ١٤٤٦ هـ
  • الحلقات
    ٢٦
  • التقييم
    ملائم
  • حقوق النشر
    © Flot.bio
  • موقع البرنامج على الويب
    Flot.bio x Philip Hemme

قد يعجبك أيضًا

للاستماع إلى حلقات ذات محتوى فاضح، قم بتسجيل الدخول.

اطلع على آخر مستجدات هذا البرنامج

قم بتسجيل الدخول أو التسجيل لمتابعة البرامج وحفظ الحلقات والحصول على آخر التحديثات.
تحديد بلد أو منطقة

أفريقيا والشرق الأوسط، والهند

آسيا والمحيط الهادئ

أوروبا

أمريكا اللاتينية والكاريبي

الولايات المتحدة وكندا